AGP Picks
View all

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on October 29, 2026

Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
Eton Pharmaceuticals to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026
Biosplice Executives to Appear on Health Uncensored with Dr. Drew on Sunday, November 1
Fortrea Reports Third Quarter 2026 Results
MINES and Associates Earns URAC Full Accreditation for Health Utilization Management
Helsinn announces UK MHRA approval of AKYNZEO® Oral Suspension
QC Healthcare, a QC Capital Group Company, Expands Connected Virtual Care Platform with National Launch of My Adult Doctor
RadNet, Inc. Announces Date of its Third Quarter 2026 Financial Results Conference Call
Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit
American Stallion Expands Into Physician-Led Telehealth and Men’s Health Services
Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform
Exogenus Therapeutics leads a €13 million EU-funded consortium to advance a new secretome-based therapy for osteoarthritis
ALLOX closes $10.5M seed financing and appoints Morten Graugaard as Chair to scale allosteric drug discovery platform and build pipeline
Cardiolyse führt KI-gestützten ECG Workspace ein: 12-Kanal-EKG-Befundung von der Erstauswertung bis zur ärztlichen Freigabe
Cardiolyse Launches AI-Powered ECG Workspace for 12-Lead ECG Review from First Read to Clinician Sign-Off
Cardiolyse lance ECG Workspace : l’analyse des ECG à 12 dérivations assistée par l’IA, de la première lecture à la validation médicale
Cardiolyse lancia ECG Workspace: refertazione degli ECG a 12 derivazioni assistita dall’IA, dalla prima lettura alla validazione medica
ADDEX INCREASES ISSUED SHARE CAPITAL  TO CREATE TREASURY SHARES
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Florida Health Daily

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.